FDA Cracks Down on Hims, Other Telehealth Companies Over Drug Ads

['.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright', 'Display Table .Wp-Block-Co-Authors-Plus-Avatar.Aligncenter Display Table Margin-Inline Auto'] News Archive - Endocrinology Advisor 2025-09-24 05:10:10

HealthDay News — Federal health officials are cracking down on telehealth companies’ promotion of unapproved versions of prescription drugs, including popular weight loss medications. On Tuesday, the U.S. Food and Drug Administration (FDA) released more than 100 warning letters aimed at both drugmakers and online health companies. Among them: Hims & Hers, a telehealth platform that has made a name by selling lower-cost versions of well-known drugs, The Associated Press said. While compounding drugs is sometimes allowed when FDA-approved versions are scarce, regulators recently said these drugs no longer qualify as in shortage. More informationLearn more about the U.S. Food and Drug Administration’s drug advertisement reforms.